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ABSTRACT
Introduction: Laser in situ keratomelieusis
(LASIK) is one of the commonest refractive
procedures performed nowadays. The dry eye
problem is nearly universal in all patients after
LASIK and it can be so annoying that the
post-operative patient satisfaction is
sometimes precluded. Conventional treatment
includes the use of artificial tears. Alternative
methods such as punctal plugs and botulinum
toxin injection can be used for the management
of post-LASIK dry eye. The aim of this study is to
compare botulinum toxin injection in the
orbicularis muscle to lacrimal punctal plugs for
the control of post-LASIK dry eye
manifestations.
Methods: This is a prospective study that
included 60 patients who had LASIK eye
surgery for correction of refractive errors.
Patients were randomly assigned to one of
three methods of dry eye management; the
first method was conventional medical
treatment with preservative-free tear
substitutes only (group A: 20 patients = 40
eyes); the second method was intraoperative
injection of botulinum toxin A (BTA) in the
orbicularis muscle below the lower punctum of
both eyes (group B: 20 patients = 40 eyes) and
the third method was intraoperative insertion
of temporary extended duration silicone
punctal plugs in the lower punctum of both
eyes (group C: 20 patients = 40 eyes).
Results: In the first follow-up visit after
2 weeks, the two test groups (B, C) showed a
statistically significant increase in both tear film
break up time (TBUT) and Schirmer test score
with a decrease in the OSDI score and daily
frequency of lubricants used in comparison to
the control group A. These differences were
maintained in the next follow-up visit but they
became statistically insignificant at the 3rd and
6th post-operative months. Complications were
encountered more in the punctal plug patients
(60%) than in BTA patients (25%) and this
difference was statistically significant.
Conclusion: The use of BTA injection to control
dry eye symptoms by inducing temporary
punctal ectropion is an effective method to
improve patient satisfaction after LASIK eye
surgery. It has higher level of patient
satisfaction and fewer complications in
comparison to punctal plugs or topical
standard dry eye treatment.
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Laser in situ keratomelieusis (LASIK) is one of
the commonest refractive procedures performed
nowadays. It involves the creation of a
superficial corneal flap by the microkeratome
followed by application of an excimer laser to
ablate a pre-determined amount of corneal
stroma correcting the refractive error and thus
improving the visual acuity [1, 2].
The dry eye problem is nearly universal in all
patients after LASIK and it can be so annoying
that the post-operative patient satisfaction is
sometimes precluded. It presents immediately
after the procedure with burning sensation,
ocular discomfort and even reduction of
post-operative visual acuity if the dry eye
keratopathy affected the central cornea. It
results from the temporary corneal
neurotrophic status that occurs upon severing
the corneal nerves during flap creation, thus
interrupting the corneal lacrimal gland reflex.
The condition usually starts to improve over the
first post-operative month and it shows nearly
complete resolution over the first post-operative
year [2, 3]. Conventional treatment includes the
use of artificial tears that act as a lubricating
agent at the ocular surface [4]. Alternative
methods such as punctal plugs and botulinum
toxin injection can be used for the management
of post LASIK dry eye.
Botulinum toxin is a potent neurotoxin
produced by the bacterium Clostridium
botulinum which elaborates eight
antigenically different exotoxins (A, B, C1, C2,
D, E, F and G). They all share the property of
interfering with the release of acetyl choline at
the neuromuscular junctions and thus resulting
in a temporary paralysis of the muscle that ends
after about 4 months when new nerve terminal
sprouts extend towards the muscle surface
[5–7]. The commercially available botulinum
toxin preparations belong to serotypes A and B
[8, 9].
Lacrimal drainage system plugs are known to
improve the signs and symptoms of moderately
dry eyes that are not improved with topical
lubrication, and they are usually well-tolerated
[10]. They can be classified according to their
location (punctal versus canalicular) and their
duration of placement (short versus extended
duration). They represent a relatively safe
option for the management of dry eye disease
but some complications have been reported
such as extrusion, migration, canaliculitis,
epiphora, chronic irritation and allergic
reaction. They can be classified into temporary
short duration plugs that are usually made of
animal collagen and last for 4–14 days, and
temporary extended duration plugs that last
from 2 to 6 months and they are made of
different materials that include silicone,
hydrogel, polydioxanone and acrylic. The
temporary extended duration punctal plugs
are the type used following refractive surgery
[10–13].
The aim of this study is to compare
botulinum toxin injection in the orbicularis
muscle to lacrimal punctal plugs for the control
of post-LASIK dry eye manifestations.
METHODS
This is a prospective study that included 60
patients who had LASIK eye surgery for
correction of refractive errors. The procedure
was performed by the same surgeon (Fouda S),
and the flap was created using a Moria M2
microkeratome with 90 or 120 blades according
to the measured pre-operative central corneal
thickness. Laser treatment was done using an
Excimer laser (192 nm UV laser) of a Schwind
Amaris 500E machine (Schwind eyetech
solution, Germany). All procedures followed
were in accordance with the ethical standards
of the responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1964, as
revised in 2013. Informed consent was obtained
from each patient before Botox injection and
punctal plugs application. All procedures were
performed between February 2015 and April
2016 in a private eye center in Egypt.
All patients received pre-operative full
medical and ocular history taking, full
ophthalmic examination, corneal imaging and
tear secretion tests. Exclusion criteria were
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pre-operative dry eye, ocular surface
irregularities, neuromuscular disorders
prohibiting botulinum toxin injection, e.g.
myaethenia gravis, or patients with known
hypersensivity to botulinum toxin.
Dry eye was assessed by both subjective and
objective methods. Eye discomfort was assessed
using an ocular surface disease index (OSDI). An
OSDI questionnaire was used to quantify the
dry eye symptoms. Subjects were asked
questions regarding the symptoms of dry eye
that they had experienced during a 1-week
recall period; the OSDI questions comprised
three different subscales: ocular symptoms,
vision-related functions, and environmental
triggers and each answer was scored on a
four-point scale ranging from zero (no
problems) to four (significant problem).
Responses to all of the questions were
combined to generate an OSDI score that
ranged from 0 to 100 using the OSDI formula:
OSDI = sum of scores 9 25/number of
questions answered. The OSDI scores and the
level of ocular disability were categorized on a
4-class scale ranging from none (OSDI total
score B12) to severe (OSDI total score C33)
[14, 15]. Tear break-up time (TBUT) and the
Schirmer tear secretion test were used to
objectively evaluate the tear film before
performing the refractive surgery and
post-operatively in all follow-up visits.
The sample size was calculated through
Epi-Info (Epidemiological Information
Package) software version 6.1. The
improvement rate for dry eyes was 83.3% with
injection of botulinum toxin and the
improvement rate for dry eyes in the punctual
plugs group was 50.0% [25]. So, at 95%
confidence interval and power of study 80%,
the sample size was calculated to be 60 patients.
Patients were randomly assigned to one of
three methods of dry eye management; the first
method was conventional medical treatment
with preservative-free tear substitutes only
(group A: 20 patients = 40 eyes); the second
method was intraoperative injection of
botulinum toxin A (BTA) in the orbicularis
muscle below the lower punctum of both eyes
(group B: 20 patients = 40 eyes) and the third
method was intraoperative insertion of a
temporary extended duration silicone punctal
plug in the lower punctum of both eyes (group
C: 20 patients = 40 eyes).
All patients were instructed to put
preservative-free tear substitute eye drops
(polyethylene glycol and propylene glycol)
Systane ultra (Alcon Laboratories, Inc., Fort
Worth, TX, USA) as needed and the frequency
was recorded in a special chart. Antibiotic eye
drops of Ofloxacin 0.3% (Oflox; Allergan
corporation, Irvine, CA, USA) and
anti-inflammatory eye drops in the form of
fluorometholone (FML; Alcon Laboratories,
Inc, Fort Worth, TX, USA) were used in the
first 2 weeks in all patients.
Group B patients were injected with 3.75
units (0.15 ml) of botulinum toxin at the end of
the LASIK procedure using a 28-gauge insulin
needle. The injection site was subcutaneous in
the orbicularis muscle of the lower lid 2 mm
below the lower punctum to induce punctal
ectropion and thus interfering with the normal
tear drainage pathway and improving dry eye
manifestations. BTA (Botox, Allergan
Corporation, Westport, Mayo, Ireland) comes
in a vial containing 100 units of freeze-dried
BTA. It was reconstituted and diluted with 4 ml
of saline, resulting in a concentration of 25
units/ml (2.5 units/0.1 ml). Before starting the
LASIK procedure, percutaneous anaesthesia was
induced by applying a eutectic mixture of local
anaesthetics (EMLA cream) over the site of
injection to avoid any undesired pain response
that may unstabilize the LASIK flap. The site
and dose of botulinum toxin injection were
chosen based on the previous work of Salhin
et al. [18].
Silicone punctal plugs (FCI Ophthalmics,
Inc., Paris, France) were inserted in the lower
punctum in both lower eyelids at the end of the
LASIK procedure in group C patients.
The patients’ data were reported at 2 and
6 weeks and 3 and 6 months post-operatively.
The main outcome measures included tear film
stability as per the TBUT test, tear secretion per
the Schirmer’s test and dry eye symptoms per
the OSDI questionnaire and the tear substitute
daily frequency by a simple daily chart. The
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TBUT test was considered positive for dry eye
when the break in the pre-corneal tear film
appeared within less than 10 s following
fluorescein dye instillation, and a positive
Schirmer’s test was considered when the
amount of the Schirmer strip wetting was less
than 5 mm after 5 min with pre-test instillation
of one drop of benoxinate hydrochloride 0.4 mg
(Benox-Eipico, Egypt) as a local anaesthetic.
Data were checked and analyzed by using
SPSS for Windows (version 16, SPSS, Chicago,
IL, USA). We checked normality and for
normally distributed data, we used the
mean ± SD and the parametric ANOVA test,
and for not normally distributed data, we used
the median (range) and the non-parametric
Kruskal–Wallis test. For all analyses, a P value
of\0.05 was considered statistically significant.
RESULTS
A total of 60 patients (120 eyes) were included
in this study; they all had uncomplicated LASIK
refractive surgery for correction of refractive
errors. Pre-operative errors included myopia,
hypermetropia and astigmatism. The spherical
equivalent for all patients ranged from ?4D to
-8.5 D with a mean of 4.25 ± 2.5D. There were
34 female patients and 26 male patients and
they were distributed as follows: 11 females to 9
males in group A (control), 12 females to 8
males in group B (BTA group) and 13 females to
7 males in group C (plugs group). The age of the
patients was 27.5 ± 2.25 years in group A,
26.2 ± 5.11 years in group B and
27.9 ± 4.7 years group C. No statistically
significant difference existed among the three
groups regarding their pre-operative TBUT,
Schirmer test results or OSDI scores.
In the first follow-up visit after 2 weeks, the
two test groups (B, C) showed a statistically
significant increase in both tear film break up
time (TBUT) and Schirmer test score with a
decrease in the OSDI score and daily frequency
of lubricants used in comparison to the control
group A. These differences were maintained in
the next follow-up visit but they became
statistically insignificant at the 3rd and 6th
post-operative months. Table 1 shows the
treatment results in every follow-up visit.
Complications were encountered more in
the punctal plug patients (60%) than in BTA
patients (25%) and this difference was
statistically significant. Among patients treated
with punctal plugs, complications included
irritation (30%) and extrusion (30%). 25% of
patients treated with BTA reported
complications in the form of increased ocular
irritation (15%) in the first 2 weeks that was
relieved by artificial tears and disappeared
nearly completely after the first 2 weeks;
moreover, 2 patients (10%) reported decreased
blinking power manifested by entrance of soap
in the eye during face washing in the morning.
Table 2 demonstrates the complications among
both treatment groups.
The overall patient satisfaction was higher
among patients receiving botulinum toxin
injection with effective control of dry eye and
few side-effects. Among the 20 patients treated
with BTA, 5 of them requested repetition of
injection after the 6-month duration of
follow-up due to residual post-LASIK dry eye
manifestations, while none of the punctal plug
group patients requested re-application of plugs
despite dry eye symptoms that existed after
6 months in about 6 patients.
DISCUSSION
According to the International Dry Eye
Workshop (DEWS), dry eye is defined as a
multifactorial disease of tears and ocular
surface with symptoms of visual disturbance,
discomfort, and tear film instability with
associated ocular inflammation and increased
tear film osmolarity [16]. LASIK surgery is
known to cause dry eye manifestations;
post-LASIK dry eye symptoms may include
burning sensations, heavy eyes, aching or sore
sensation, red eye, reflex tearing and even
blurring of vision. [17] Both botulinum
toxin-induced punctal ectropion and punctal
occlusion with plugs prolong the effects of
lubricants and preserves natural tears.
This study directly compares botulinum
toxin injection with punctal plugs for the
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TBUT 4.95 ± 1.49 s 7.12 ± 1.33 s 6.87 ± 1.76 s 11.935 \0.0001
Schirmer test 4.64 ± 2.11 mm 8.4 ± 4.37 mm 7.63 ± 3.15 mm 7.07 0.002
4.32 (1.98–8.3) 8.9 (3.1–16.7) 7.42 (3.1–14.2)
OSDI score 25.29 ± 11.8 12.33 ± 8.59 15.65 ± 10.4 12.273 \0.0001
24 (7.4–46.8) 11.8 (2.2–28.7) 16 (4.3–35.8) 4.530
Number of times of lubricants
use/day
8.22 ± 2.19 5.71 ± 3.10 6.28 ± 2.92 0.015
8 (4–13) 5 (1–10) 6 (2–11)
6 weeks
TBUT 4.94 ± 1.23 s 7.01 ± 1.61 s 6.92 ± 2.27 s 6.974 0.002
6.551
Schirmer test 5.14 ± 1.91 mm 8.4 ± 4.37 mm 8.87 ± 3.88 mm 0.003
5 (2–8) 8 (3–16) 9 (3–15)
OSDI score 24.11 ± 9.33 11.57 ± 7.83 13.98 ± 8.72 11.840 \0.0001
24 (4–41) 12 (2–33) 14.5 (3–38) 3.939
Number of times of lubricants
use/day
6.36 ± 2.47 4.57 ± 2.16 4.11 ± 3.28 0.025
6 (2–12) 5 (1–10) 4 (1–9)
3 months
TBUT 8.17 ± 2.02 s 8.77 ± 1.42 s 9.33 ± 2.39 s 1.710 0.190
Schirmer test 9.77 ± 1.63 mm 10.48 ± 3.86 mm 10.4 ± 3.66 mm 0.231 0.794
OSDI score 15.18 ± 5.63 11.22 ± 4.98 12.42 ± 8.31 1.970 0.149
15 (6–25) 11 (3–19) 13 (4–23) 0.717 0.493
Number of times of lubricants
use/day
3.52 ± 2.15 2.59 ± 2.83 2.93 ± 2.43
4 (1–8) 2 (1–6) 3 (1–7)
6 months
TBUT 8.98 ± 2.23 s 8.90 ± 2.01 s 9.05 ± 1.76 s 0.028 0.972
Schirmer test 10.24 ± 1.91 mm 11.02 ± 3.37 mm 11.04 ± 3.56 mm 0.353 0.704
OSDI score 12.74 ± 4.16 11.12 ± 3.26 11.81 ± 3.20 0.601 0.552
Number of times of lubricants
use/day
2.41 ± 1.62 1.92 ± 2.20 1.76 ± 2.32 0.536
2 (1–6) 1 (1–5) 1 (1–5) 0.588
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control of post-LASIK dry eye manifestations.
Using these two methods of treatment carries
the potential advantage of their temporary
effect that suits the temporary nature of this
particular type of dry eye. Silicone plugs were
chosen because of their relative availability and
their typical persistence for a longer period than
collagen plugs; so, they are, theoretically, more
suitable for comparison with BTA injections as
they both last for a similar duration.
In this study, all the dry eye parameters were
better for the BTA and plug group than the tear
substitute eye drops-only group in the early
post-operative period. Then, the differences
became statistically insignificant starting from
the 3rd month which could be attributed to the
fading out of BTA effect and the expected
improvement of the post-LASIK dry eye
condition with regeneration of the
neurotrophic corneal neurons.
Although the two methods of intervention
carry a risk of potential complications, their
significant effect in the reduction of post-LASIK
dry eye manifestations makes them a valuable
tool in our armamentorium for the
management of this complication, especially
in the first 3 months following LASIK, taking
into account that the effect of these
interventions fades away after 3 months with
similar effects from tear substitutes in
controlling any residual dry eye manifestations.
Sahlin et al. [18]were thefirst to study the effect
of botulinum toxin injection on tear drainage in
patients with dry eye. According to their study,
limiting the toxin injection into the lower eye lid
carried better results regarding the patient
satisfaction. They attributed this to the minimal
upper eyelid retraction that was encountered after
the injection intobothupper and lower eye lid and
to the exaggerated weakening of the blink power
causing some ocular irritation.
Isshiki et al. [19] found that there is
significant improvement in both the Schirmer
test and TBUT test results with reduction in
high-order ocular aberrations in patients of
blepharospasm treated with botulinum toxin.
In addition to the previously mentioned tests,
Park et al. [20] added lower lid tear meniscus
height measured by optical coherence
tomography and dacryoscintigraphy using
99 m technetium pertechnetate with similar
results, confirming the improvement of dry
eye manifestations after BTA injection in
blepharospasm patients. Serna-Ojeda et al. [21]
studied the effect of BTA injection on TBUT,
Schirmer’s test and corneal and conjunctival
staining by performing a comparative
eye-to-eye interventional study. They found
that the eyes in the active treatment group
showed better scores compared with the sham
group with no adverse events reported.
On the other hand, Price et al. [22] and
Horwath-Winter et al. [23] did not find any
improvement of in the dry eye disease symptoms
nor Schirmer test results among their patients
who suffered from both dry eye disease and
blepharospasm after they received BTA
injections for treatment of blepharospasm, and
this was attributed to the inhibitory effect of
botulinum toxin on the secretion of the lacrimal
gland as treatment of the aforementioned facial
dystonias involved injection of the toxin in areas
close to the lacrimal gland carrying the risk of
diffusion of the toxin to the gland.
Table 2 Complications of both botulinum toxin and punctal plugs
Complication Number (%) P
Group B (botulinum toxin) Group C (plugs) 0.0311
None 15 (75%) 8 (40%)
Irritation 3 (15%) 6 (30%)
Extrusion 0 6 (30%)
Decreased blinking power 2 (10%) 0
Total number of patient complications (%) 7 (35%) 10 (55%)
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Alfawaz et al. [24] evaluated the effect of
punctal plug use in preventing dry eyes after
LASIK by comparing the results of the TBUT
test, Schirmer’s test and OSDI in both eyes of
the same patient treated with a lower punctal
plug in one eye and using the other eye as
control. They concluded that insertion of
punctal plugs was significantly effective in
improving dry eye symptoms and patient
satisfaction after LASIK. Bukhari [25] compared
both the botulinum toxin with the punctal
plugs in the management of patients with
severe dry eye that is not controlled by the
standard topical medication. In her study, the
patient satisfaction was significantly higher in
the botulinum toxin group with better control
of symptoms and fewer side-effects.
To our knowledge, this study is the first to
introduce botulinum toxin injection for the
control of post-LASIK dry eye which is a
particular entity of dry eye due to its
temporary nature and the relatively younger
age group than the majority of dry eye patients.
One of the limitations of this study is that
the comparison between different degrees of dry
eye severity and to which extent did each
degree of severity improve on each modality
of treatment was not possible, because the
interference was done in advance during the
initial LASIK surgery as the post-LASIK dry eye is
nearly a universal finding and the aim of our
interventions was to improve the patient
satisfaction in the first 3 months following
LASIK, during which dry eye manifestations
are expected to be maximum. Another
limitation of the study is the small sample size.
Future studies comparing the effect of BTA and
plugs onpost-LASIKdry eye shouldbe conducted,
taking into account the introduction of the two
methods after actual development of post-LASIK
dry eye and thus allowing classification of the dry
eye according to severity to assess which patients
(moderate vs. severe) might obtain the most
benefits from the proposed treatments.
CONCLUSION
The use of BTA injection to control dry eye
symptoms by inducing temporary punctal
ectropion is an effective method to improve
the patient satisfaction after LASIK eye
surgery. It has a higher level of patient
satisfaction and fewer complications in
comparison to punctal plugs or topical
standard dry eye treatment.
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